MarketInOut Stock Screener Log In | Sign Up
 

Iovance Biotherapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 07/21/2026 10:30
Iovance Biotherapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,232.51 mln
Float388 mln
Earnings Date08/06/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-2.71
Likely reliable

Relative Strength

98 / 100
Top performer

Debt / Equity

0.07
Debt-free

ROE

-49.30
Deeply negative

Dividend Yield

0.00%
No dividend

Business Description

Iovance Biotherapeutics is a California-based company that creates cancer treatments by extracting and multiplying a patient's own immune cells to fight tumors. Its lead product, Amtagvi, is approved for adults with advanced melanoma that has not responded to prior treatment, while Proleukin serves patients with melanoma and kidney cancer. The company has a broad pipeline targeting several other cancers, including cervical, lung, and head and neck cancers, and works alongside major research institutions and pharmaceutical partners to advance its therapies.

Key Fundamentals

EPS-0.92
ROE-49.30
RPS0.75
ROIC-73.12
ROA-38.31
EBITDA, mln-311
EV / EBITDA-5.21
EV / EBIT-4.53
Revenue, mln286
EV / Revenue5.68

Financial Strength

Altman Z-Score0.72
Piotroski F-Score 4 / 9
Beneish M-Score-2.71
Short Ratio7.32
Short % of Float24.10

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 36.39% 99 / 100   
1 Month 37.08% 98 / 100   
2 Months 54.91% 95 / 100   
6 Months 127% 98 / 100   
1 Year 140% 95 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us